5S9-23588-12366
3 vaccinations
3 coded responses
38 check-ins
3 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 800 / CO
- Registered
- 2020-12-17
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-17
Registered in v-safe
-
2020-12-17
Dose 1 — Pfizer-BioNTech
- 2020-12-17
- 2020-12-18
- 2020-12-19
- 2020-12-20
- 2020-12-21
- 2020-12-22
-
2020-12-26
Health check-in — day 7, dose 1Feeling: Fair · Fatigue or tiredness, Nausea, Abdominal pain · Be unable to do your normal daily activitiesAdult check-in
-
2020-12-26
Report sent to call center — day 7, dose 1Be unable to do your normal daily activities1 call case(s)
- 2020-12-31
-
2021-01-07
Dose 2 — Pfizer-BioNTech
- 2021-01-07
-
2021-01-09
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-01-10
- 2021-01-11
-
2021-01-12
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Headache, Fatigue or tirednessAdult check-in
- 2021-01-13
- 2021-01-14
- 2021-01-21
- 2021-01-28
- 2021-02-04
- 2021-02-11
- 2021-02-18
- 2021-04-08
- 2021-07-09
-
2021-09-11
Dose 3 — Pfizer-BioNTechCo-administered: Flu:Tetanus
- 2021-09-11
- 2021-09-12
- 2021-09-13
- 2021-09-14
- 2021-09-15
- 2021-09-16
- 2021-09-17
- 2021-09-18
-
2021-09-25
Survey response — day 14, dose 3MedDRA: Nausea — Feeling: GoodFree text: NauseaMedDRA releases: 2024-11 · check-in free text available
- 2021-10-04
- 2021-10-09
- 2021-10-16
- 2021-10-23
- 2021-12-11
-
2022-03-12
Survey response — 6 months, dose 3MedDRA: Fungal skin infection — Feeling: GoodFree text: Fungal rashMedDRA releases: 2024-11 · check-in free text available
-
2022-09-11
Survey response — 12 months, dose 3MedDRA: Dyspnoea, Menstruation irregular, Night sweats — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Shortness of breath, nightsweats, irregular periodMedDRA releases: 2024-11 · check-in free text available
-
2022-09-11
Report sent to call center — 12 months, dose 3Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-09-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-17 | Pfizer-BioNTech | |
| 2 | 2021-01-07 | Pfizer-BioNTech | |
| 3 | 2021-09-11 | Pfizer-BioNTech | Flu:Tetanus |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2020-12-26 | priority 2/3 | |
| 2022-09-11 | Unsuccessful |
Free text
Release 9 — day 14, dose 3
Symptoms: Nausea
Release 11 — 6 months, dose 3
Symptoms: Fungal rash
Release 12 — 12 months, dose 3
Symptoms: Shortness of breath, nightsweats, irregular period
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Dyspnoea | · | · | ✓ |
| SD | Fungal skin infection | · | · | ✓ |
| SD | Menstruation irregular | · | · | ✓ |
| SD | Nausea | · | · | ✓ |
| SD | Night sweats | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release